Format

Send to

Choose Destination
Transfusion. 2010 Aug;50(8):1690-701. doi: 10.1111/j.1537-2995.2010.02644.x. Epub 2010 Apr 15.

Generation of HLA-deficient platelets from hematopoietic progenitor cells.

Author information

1
Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.

Abstract

BACKGROUND:

Exposure to allogeneic blood products often leads to the development of human leukocyte antigen (HLA) antibodies. Refractoriness to platelet (PLT) transfusion caused by alloimmunization against HLA Class I antigens constitutes a significant clinical problem.

STUDY DESIGN AND METHODS:

We developed an RNA interference (RNAi)-based approach to silence the expression of HLA Class I molecules on PLTs derived from CD34+ progenitor cells. A lentiviral-based system was used to express short-hairpin RNA (shRNA) targeting β2-microglobulin (β2m) transcripts in CD34+ progenitor cells. Differentiation to PLTs was performed by incubating progenitor cells in the presence of thrombopoietin and interleukin-3.

RESULTS:

The transduction of RNAi cassettes containing the sequences for shRNAs targeting β2m caused up to 85% reduction of progenitor cells HLA Class I antigen expression, which was maintained in the culture-derived PLTs. The HLA-deficient PLTs derived from HLA-silenced CD34+ cells proved to be fully functional in in vitro tests when compared to peripheral blood-derived PLTs.

CONCLUSIONS:

Our data show that in vitro generating HLA Class I-deficient PLTs from hematopoietic progenitor cells prove to be feasible. As malignancy risks associated with insertional mutagenesis are not to be expected in anucleated PLTs, provision of HLA-deficient PLTs from large-scale production units may become reality in the management of patients suffering from PLT transfusion refractoriness.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center